immunotherapy
BMS’ Opdivo scores eighth approval in Europe for bladder cancer
June 5, 2017Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, Europe, European Commission, bladder cancer, immunotherapy
Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …
T cells found to ‘acquire knowledge’ to take fight to metastatic cancer
May 17, 2017Research and Development Cancer, T cell, immunotherapy
T cells are widely known as being crucial in the fight against cancer within the body but little was known, …
Immune system influences immunotherapy effectiveness, research shows
April 3, 2017Research and Development, Sales and Marketing immunotherapy, nivolumab, opdivo
Preliminary research conducted at the University of Pittsburgh Cancer Institute (UPCI) has discovered a link between levels of certain immune …
Immunotherapy: The three major treatments that are changing cancer prognoses
March 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq
The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …
Promising anti-cocaine treatment aims for human trials within a year
March 1, 2017Research and Development University of Cincinnati, cocaine, immunotherapy
Researchers at the University of Cincinnati (UC) have developed a monocloncal antibody designed to treat cocaine addiction; its successful showing …
The March 2017 issue of Pharmafocus is now live!
February 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo
The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …
FDA clears Opdivo to treat most common form of bladder cancer
February 6, 2017Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …
New immunotherapy-based cancer research limits cancer spread by 75%
January 12, 2017Medical Communications, Research and Development Cancer, cancer research, immunotherapy
Research conducted by the Sanger Institute in Cambridge has discovered 23 new genes associated with cancer cell’s spread through the …
MSD looks to jump the gun with combination immunotherapy application
January 11, 2017Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda
MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …
Amgen and Immatics enter $1bn immuno-oncology partnership
January 9, 2017Research and Development, Sales and Marketing Amgen, immatics, immunotherapy
Amgen has announced it is to join forces with cancer immunotherapy biotech Immatics Biotechnologies in a partnership potentially worth over …
AstraZeneca’s head and neck cancer treatment clinical trials put on hold
October 31, 2016Sales and Marketing AstraZeneca, clinical hold, clinical trials, immunotherapy, phase III
AstraZeneca, the Cambridge-based British company, had recruitment for its final stage Phase III trials placed on partial hold. The drug …
Roche’s immunotherapy cancer drug given FDA approval
October 19, 2016Research and Development Cancer, FDA, Genentech, Roche, immunotherapy, lung cancer
Coming off the back of earlier positive news this month, Roche has revealed that their drug, Tecentriq, has been given …
Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation
UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …
Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma
June 10, 2016Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma
Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma. The company said …
FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq
May 19, 2016Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq
Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …
Latest content
Five Facts about cardiovascular disease
